Great Strides in the Treatment of HIV
January 9, 2015
A team of chemists working for Shionogi & Co., Ltd. and GlaxoSmithKline LLC (GSK) developed a heterocyclic compound named Dolutegravir, discovered to be uniquely effective in the treatment of HIV infection. Wenderoth obtained the U.S patent covering Dolutegravir for GSK and Shionogi, as well as corresponding patents in over 50 countries around the world. This drug has since been approved by the FDA, Health Canada and the European Commission, and is marketed as TIVICAY® by ViiV Healthcare Company, a joint venture between GSK, Pfizer and Shionogi. TIVICAY® is expected to have potential sales of $5 billion per year.